#BEGIN_DRUGCARD DB00336

# AHFS_Codes:
08:36.00
40:28.08

# ATC_Codes:
B05CA03
D08AF01
D09AA03
P01CC02
S01AX04
S02AA02

# Absorption:
Well absorbed.

# Biotransformation:
Nitrofurans, including nitrofural, undergo metabolic reduction at the nitro group to generate reactive species which can covalently bind to cellular macromolecules (Polnaszek et al., 1984; Kutcher & McCalla, 1984; McCalla 1979; McCalla et al., 1975).

# Brand_Mixtures:
Not Available

# Brand_Names:
Actin-N
Aldomycin
Alfucin
Amifur
Babrocid
Becafurazone
Biofuracina
Biofurea
Chemofuran
Chixin
Cocafurin
Coxistat
Dermofural
Dymazone
Dynazone
Eldezol
Eldezol F-6
Fedacin
Flavazone
Fracine
Furacilin
Furacillin
Furacin
Furacin Soluble Dressing
Furacin Topical Cream
Furacin Topical Solution
Furacin-E
Furacin-HC
Furacine
Furacinetten
Furacoccid
Furacort
Furacycline
Furaderm
Furagent
Furalcyn
Furaldon
Furalone
Furametral
Furan-Ofteno
Furaplast
Furaseptyl
Furaskin
Furatsilin
Furaziline
Furazin
Furazina
Furazol W
Furazone
Furazyme
Furesol
Furfurin
Furosem
Fuvacillin
Hemofuran
Ibiofural
Mammex
Mastofuran
Monafuracin
Monafuracis
Monofuracin
NF-7
Nefco
Nifucin
Nifurid
Nifuzon
Nitrofural
Nitrofuran
Nitrofurane
Nitrofurol
Nitrozone
Otofural
Otofuran
Sanfuran
Spray-Dermis
Spray-Foral
Vabrocid
Vadrocid
Yatrocin

# CAS_Registry_Number:
59-87-0

# ChEBI_ID:
Not Available

# Chemical_Formula:
C6H6N4O4

# Chemical_IUPAC_Name:
[(E)-[(5-nitrofuran-2-yl)methylidene]amino]urea

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
575011

# Description:
A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial wounds, burns, ulcers, and skin infections. Nitrofurazone has also been administered orally in the treatment of trypanosomiasis. [PubChem]

# Dosage_Forms:
Capsule	Oral
Dressing	Topical
Liquid	Intramuscular
Ointment	Topical
Powder	Oral
Powder	Topical
Powder, for solution	Oral
Solution	Intrauterine
Solution	Intravenous
Solution	Oral
Solution	Topical
Tablet	Oral

# Drug_Category:
Anti-Infective Agents
Anti-Infective Agents, Local
Anti-Infective Agents, Urinary
Trypanocidal Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.23

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
210 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Nitrofurazone

# HET_ID:
NFZ

# Half_Life:
5 hours

# InChI_Identifier:
InChI=1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+

# InChI_Key:
InChIKey=IAIWVQXQOWNYOU-FPYGCLRLSA-N

# Indication:
For the treatement of bacterial skin infections including pyodermas, infected dermatoses and infections of cuts, wounds, burns and ulcers due to susceptible organisms.

# KEGG_Compound_ID:
C08042

# KEGG_Drug_ID:
D00862

# LIMS_Drug_ID:
336

# Mechanism_Of_Action:
The exact mechanism of action is unknown. Nitrofurazone inhibits several bacterial enzymes, especially those involved in the aerobic and anaerobic degradation of glucose and pyruvate. This activity is believed also to affect pyruvate dehydrogenase, citrate synthetase, malate dehydrogenase, glutathione reductase, and pyruvate decarboxylase.

# Melting_Point:
238 dec °C

# Molecular_Weight_Avg:
198.1362

# Molecular_Weight_Mono:
198.0389047

# Organisms_Affected:
Gram negative and gram positive bacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164754877

# Pharmacology:
Nitrofurazone is a topical antibacterial agent indicated as an adjunctive therapy for second and third degree burns when resistance to other agents is a real or potential problem. Nitrofurazone is also indicated in skin grafting when bacterial contamination may cause graft rejection or donor site infection, especially in hospitals with a history of resistant bacteria.

# Predicted_LogP_Hydrophobicity:
0.23

# Predicted_LogS:
-2.9

# Predicted_Water_Solubility:
2.68e-01 g/l

# Primary_Accession_No:
DB00336

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5447130

# PubChem_Substance_ID:
46506509

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00050

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
NFZ
Nitrofurazan

# Synthesis_Reference:
Not Available

# Toxicity:
Rat LD<sub>50</sub> = 590 mg/kg; Allergic contact dermatitis is the most frequently reported adverse effect, occurring in approximately 1 % of patients treated.

# Update_Date:
2013-02-08 16:19:16 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Nitrofurazone

# pKa_Isoelectric_Point:
10

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
XDH

# Phase_1_Metabolizing_Enzyme_1_ID:
3947

# Phase_1_Metabolizing_Enzyme_1_Name:
Xanthine dehydrogenase/oxidase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase
MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDR
LQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGI
VMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCC
MNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQAS
TLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFG
AACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISD
LNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSA
FKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKE
ELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLD
PTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRY
ENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDK
VTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDL
KKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKM
LGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGR
HPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGR
LCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKL
EGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGA
LLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAA
SVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLG
YSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAF
VQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAV
GEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVT
GVPENCKPWSVRV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P47989

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_2_ID:
4119

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P10635

# Drug_Target_1_Cellular_Location:
Bacterial cell membrane
peripheral membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X04105

# Drug_Target_1_GenBank_ID_Protein:
42473

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
poxB

# Drug_Target_1_Gene_Sequence:
>1719 bp
ATGAAACAAACGGTTGCAGCTTATATCGCCAAAACACTCGAATCGGCAGGGGTGAAACGC
ATCTGGGGAGTCACAGGCGACTCTCTGAACGGTCTTAGTGACAGTCTTAATCGCATGGGC
ACCATCGAGTGGATGTCCACCCGCCACGAAGAAGTGGCGGCCTTTGCCGCTGGCGCTGAA
GCACAACTTAGCGGAGAACTGGCGGTCTGCGCCGGATCGTGCGGCCCCGGCAACCTGCAC
TTAATCAACGGCCTGTTCGATTGCCACCGCAATCACGTTCCGGTACTGGCGATTGCCGCT
CATATTCCCTCCAGCGAAATTGGCAGCGGCTATTTCCAGGAAACCCACCCACAAGAGCTA
TTCCGCGAATGTAGTCACTATTGCGAGCTGGTTTCCAGCCCGGAGCAGATCCCACAAGTA
CTGGCGATTGCCATGCGCAAAGCGGTGCTTAACCGTGGCGTTTCGGTTGTCGTGTTACCA
GGCGACGTGGCGTTAAAACCTGCGCCAGAAGGGGCAACCATGCACTGGTATCATGCGCCA
CAACCAGTCGTGACGCCGGAAGAAGAAGAGTTACGCAAACTGGCGCAACTGCTGCGTTAT
TCCAGCAATATCGCCCTGATGTGTGGCAGCGGCTGCGCGGGGGCGCATAAAGAGTTAGTT
GAGTTTGCCGGGAAAATTAAAGCGCCTATTGTTCATGCCCTGCGCGGTAAAGAACATGTC
GAATACGATAATCCGTATGATGTTGGAATGACCGGGTTAATCGGCTTCTCGTCAGGTTTC
CATACCATGATGAACGCCGACACGTTAGTGCTACTCGGCACGCAATTTCCCTACCGCGCC
TTCTACCCGACCGATGCCAAAATCATTCAGATTGATATCAACCCAGCCAGCATCGGCGCT
CACAGCAAGGTGGATATGGCACTGGTCGGCGATATCAAGTCGACTCTGCGTGCATTGCTT
CCATTGGTGGAAGAAAAAGCCGATCGCAAGTTTCTGGATAAAGCGCTGGAAGATTACCGC
GACGCCCGCAAAGGGCTGGACGATTTAGCTAAACCGAGCGAGAAAGCCATTCACCCGCAA
TATCTGGCGCAGCAAATTAGTCATTTTGCCGCCGATGACGCTATTTTCACCTGTGACGTT
GGTACGCCAACGGTGTGGGCGGCACGTTATCTAAAAATGAACGGCAAGCGTCGCCTGTTA
GGTTCGTTTAACCACGGTTCGATGGCTAACGCCATGCCGCAGGCGCTGGGTGCGCAGGCG
ACAGAGCCAGAACGTCAGGTGGTCGCCATGTGCGGCGATGGCGGTTTTAGCATGTTGATG
GGCGATTTCCTCTCAGTAGTGCAGATGAAACTGCCAGTGAAAATTGTCGTCTTTAACAAC
AGCGTGCTGGGCTTTGTGGCGATGGAGATGAAAGCTGGTGGCTATTTGACTGACGGCACC
GAACTACACGACACAAACTTTGCCCGCATTGCCGAAGCGTGCGGCATTACGGGTATCCGT
GTAGAAAAAGCGTCTGAAGTTGATGAAGCCCTGCAACGCGCCTTCTCCATCGACGGTCCG
GTGTTGGTGGATGTGGTGGTCGCCAAAGAAGAGTTAGCCATTCCACCGCAGATCAAACTC
GAACAGGCCAAAGGTTTCAGCCTGTATATGCTGCGCGCAATCATCAGCGGACGCGGTGAT
GAAGTGATCGAACTGGCGAAAACAAACTGGCTAAGGTAA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
2663858	Grabau C, Chang YY, Cronan JE Jr: Lipid binding by Escherichia coli pyruvate oxidase is disrupted by small alterations of the carboxyl-terminal region. J Biol Chem. 1989 Jul 25;264(21):12510-9.
3016647	Grabau C, Cronan JE Jr: Nucleotide sequence and deduced amino acid sequence of Escherichia coli pyruvate oxidase, a lipid-activated flavoprotein. Nucleic Acids Res. 1986 Jul 11;14(13):5449-60.
3902830	Recny MA, Grabau C, Cronan JE Jr, Hager LP: Characterization of the alpha-peptide released upon protease activation of pyruvate oxidase. J Biol Chem. 1985 Nov 15;260(26):14287-91.
8022274	Chang YY, Wang AY, Cronan JE Jr: Expression of Escherichia coli pyruvate oxidase (PoxB) depends on the sigma factor encoded by the rpoS(katF) gene. Mol Microbiol. 1994 Mar;11(6):1019-28.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
845

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
62012

# Drug_Target_1_Name:
Pyruvate dehydrogenase [cytochrome]

# Drug_Target_1_Number_of_Residues:
572

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00205	TPP_enzyme_M
PF02775	TPP_enzyme_C
PF02776	TPP_enzyme_N

# Drug_Target_1_Protein_Sequence:
>Pyruvate dehydrogenase [cytochrome]
MKQTVAAYIAKTLESAGVKRIWGVTGDSLNGLSDSLNRMGTIEWMSTRHEEVAAFAAGAE
AQLSGELAVCAGSCGPGNLHLINGLFDCHRNHVPVLAIAAHIPSSEIGSGYFQETHPQEL
FRECSHYCELVSSPEQIPQVLAIAMRKAVLNRGVSVVVLPGDVALKPAPEGATMHWYHAP
QPVVTPEEEELRKLAQLLRYSSNIALMCGSGCAGAHKELVEFAGKIKAPIVHALRGKEHV
EYDNPYDVGMTGLIGFSSGFHTMMNADTLVLLGTQFPYRAFYPTDAKIIQIDINPASIGA
HSKVDMALVGDIKSTLRALLPLVEEKADRKFLDKALEDYRDARKGLDDLAKPSEKAIHPQ
YLAQQISHFAADDAIFTCDVGTPTVWAARYLKMNGKRRLLGSFNHGSMANAMPQALGAQA
TEPERQVVAMCGDGGFSMLMGDFLSVVQMKLPVKIVVFNNSVLGFVAMEMKAGGYLTDGT
ELHDTNFARIAEACGITGIRVEKASEVDEALQRAFSIDGPVLVDVVVAKEELAIPPQIKL
EQAKGFSLYMLRAIISGRGDEVIELAKTNWLR

# Drug_Target_1_Reaction:
pyruvate + ferricytochrome b1 + H2O = acetate + CO2 + ferrocytochrome b1

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P07003

# Drug_Target_1_SwissProt_Name:
POXB_ECOLI

# Drug_Target_1_Synonyms:
EC 1.2.2.2
POX
Pyruvate dehydrogenase [Ubiquinone]
Pyruvate oxidase

# Drug_Target_1_Theoretical_pI:
6.24

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16275032	Vega-Teijido M, Caracelli I, Zukerman-Schpector J: Conformational analyses and docking studies of a series of 5-nitrofuran- and 5-nitrothiophen-semicarbazone derivatives in three possible binding sites of trypanothione and glutathione reductases. J Mol Graph Model. 2006 Mar;24(5):349-55. Epub 2005 Nov 7.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M13141

# Drug_Target_2_GenBank_ID_Protein:
146248

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
gor

# Drug_Target_2_Gene_Sequence:
>1353 bp
ATGACTAAACACTATGATTACATCGCCATCGGCGGCGGCAGCGGCGGTATCGCCTCCATC
AACCGCGCGGCTATGTACGGCCAGAAATGTGCGCTGATTGAAGCCAAAGAGCTGGGCGGC
ACCTGCGTAAATGTTGGCTGTGTGCCGAAAAAAGTGATGTGGCACGCGGCGCAAATCCGT
GAAGCGATCCATATGTACGGCCCGGATTATGGTTTTGATACCACTATCAATAAATTCAAC
TGGGAAACGTTGATCGCCAGCCGTACCGCCTATATCGACCGTATTCATACTTCCTATGAA
AACGTGCTCGGTAAAAATAACGTTGATGTAATCAAAGGCTTTGCCCGCTTCGTTGATGCC
AAAACGCTGGAGGTAAACGGCGAAACCATCACGGCCGATCATATTCTGATCGCCACAGGC
GGTCGTCCGAGCCACCCGGATATTCCGGGCGTGGAATACGGTATTGATTCTGATGGCTTC
TTCGCCCTTCCTGCTTTGCCAGAGCGCGTGGCGGTTGTTGGCGCGGGTTACATCGCCGTT
GAGCTGGCGGGCGTGATTAACGGCCTCGGCGCGAAAACGCATCTGTTTGTGCGTAAACAT
GCGCCGCTGCGCAGCTTCGACCCGATGATTTCCGAAACGCTGGTCGAAGTGATGAACGCC
GAAGGCCCGCAGCTGCACACCAACGCCATCCCGAAAGCGGTAGTGAAAAATACCGATGGT
AGCCTGACGCTGGAGCTGGAAGATGGTCGCAGTGAAACGGTGGATTGCCTGATTTGGGCG
ATTGGTCGCGAGCCTGCCAATGACAACATCAACCTGGAAGCCGCTGGCGTTAAAACTAAC
GAAAAAGGCTATATCGTCGTCGATAAATATCAAAACACCAATATTGAAGGTATTTACGCG
GTGGGCGATAACACGGGTGCAGTGGAGCTGACACCGGTGGCAGTTGCAGCGGGTCGCCGT
CTCTCTGAACGCCTGTTTAATAACAAGCCGGATGAGCATCTGGATTACAGCAACATTCCG
ACCGTGGTCTTCAGCCATCCGCCGATTGGTACTGTTGGTTTAACGGAACCGCAGGCGCGC
GAGCAGTATGGCGACGATCAGGTGAAAGTGTATAAATCCTCTTTCACCGCGATGTATACC
GCCGTCACCACTCACCGCCAGCCGTGCCGCATGAAGCTGGTGTGCGTTGGATCGGAAGAG
AAGATTGTCGGTATTCACGGCATTGGCTTTGGTATGGACGAAATGTTGCAGGGCTTCGCG
GTGGCGCTGAAGATGGGGGCAACCAAAAAAGACTTCGACAATACCGTCGCCATTCACCCA
ACGGCGGCAGAAGAGTTCGTGACAATGCGTTAA

# Drug_Target_2_General_Function:
RNA processing and modification

# Drug_Target_2_General_References:
2006135	Ermler U, Schulz GE: The three-dimensional structure of glutathione reductase from Escherichia coli at 3.0 A resolution. Proteins. 1991;9(3):174-9.
3521741	Greer S, Perham RN: Glutathione reductase from Escherichia coli: cloning and sequence analysis of the gene and relationship to other flavoprotein disulfide oxidoreductases. Biochemistry. 1986 May 6;25(9):2736-42.
8041620	Sofia HJ, Burland V, Daniels DL, Plunkett G 3rd, Blattner FR: Analysis of the Escherichia coli genome. V. DNA sequence of the region from 76.0 to 81.5 minutes. Nucleic Acids Res. 1994 Jul 11;22(13):2576-86.
8061609	Mittl PR, Schulz GE: Structure of glutathione reductase from Escherichia coli at 1.86 A resolution: comparison with the enzyme from human erythrocytes. Protein Sci. 1994 May;3(5):799-809.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
327

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
48773

# Drug_Target_2_Name:
Glutathione reductase

# Drug_Target_2_Number_of_Residues:
450

# Drug_Target_2_PDB_ID:
1GET

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_2_Protein_Sequence:
>Glutathione reductase
MTKHYDYIAIGGGSGGIASINRAAMYGQKCALIEAKELGGTCVNVGCVPKKVMWHAAQIR
EAIHMYGPDYGFDTTINKFNWETLIASRTAYIDRIHTSYENVLGKNNVDVIKGFARFVDA
KTLEVNGETITADHILIATGGRPSHPDIPGVEYGIDSDGFFALPALPERVAVVGAGYIAV
ELAGVINGLGAKTHLFVRKHAPLRSFDPMISETLVEVMNAEGPQLHTNAIPKAVVKNTDG
SLTLELEDGRSETVDCLIWAIGREPANDNINLEAAGVKTNEKGYIVVDKYQNTNIEGIYA
VGDNTGAVELTPVAVAAGRRLSERLFNNKPDEHLDYSNIPTVVFSHPPIGTVGLTEPQAR
EQYGDDQVKVYKSSFTAMYTAVTTHRQPCRMKLVCVGSEEKIVGIHGIGFGMDEMLQGFA
VALKMGATKKDFDNTVAIHPTAAEEFVTMR

# Drug_Target_2_Reaction:
2 glutathione + NADP+ = glutathione disulfide + NADPH + H+

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Maintains high levels of reduced glutathione in the cytosol

# Drug_Target_2_SwissProt_ID:
P06715

# Drug_Target_2_SwissProt_Name:
GSHR_ECOLI

# Drug_Target_2_Synonyms:
EC 1.8.1.7
GR
GRase

# Drug_Target_2_Theoretical_pI:
5.88

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Y00129

# Drug_Target_3_GenBank_ID_Protein:
41989

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
mdh

# Drug_Target_3_Gene_Sequence:
>939 bp
ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGGTATTGGCCAGGCGCTTGCACTACTGTTA
AAAACCCAACTGCCTTCAGGTTCAGAACTCTCTCTGTATGATATCGCTCCTGTGACTCCC
GGTGTGGCTGTCGATCTGAGCCATATCCCTACTGCTGTGAAAATCAAAGGTTTTTCTGGT
GAAGATGCGACTCCGGCGCTGGAAGGCGCAGATGTCGTTCTTATCTCTGCAGGCGTACGG
CGTAAACCGGGTATGGATCGTTCCGACCTGTTTAACGTTAACGCCGGCATCGTGAAAAAC
CTGGTACAGCAAGTTGCGAAAACCTGCCCGAAAGCGTGCATTGGTATTATCACTAACCCG
GTTAACACCACAGTTGCAATTGCTGCTGAAGTGCTGAAAAAAGCCGGTGTTTATGACAAA
AACAAACTGTTGGGCGTTACCACGCTGGATATCATTCGTTCCAACACCTTTGTTGCGGAA
CTGAAAGGCAAACAGCCTGGCGAAGTTGAAGTGCCGGTTATTGGCGGTCACTCTGGTGTT
ACCATTCTGCCGCTGCTGTCACAGGTTCCTGGCGTTAGTTTTACCGAGCAGGAAGTCGCT
GATCTGACCAAACGCATCCAGAACGCGGGTACTGAAGTGGTTGAAGCGAAGGCCGGTGGC
GGGTCTGCAACCCTGTCTATGGGCCAGGCAGCTGCACGTTTTGGTCTGTCTCTGGTTCGT
GCACTGCAGGGCGAACAAGGCGTTGTCGAATGTGCCTACGTTGAAGGCGACGGTCAGTAC
GCCCGTTTCTTCTCTCAACCGCTGCTGCTGGGTAAAAACGGCGTGGAAGAGCGTAAATCT
ATCGGTACCCTGAGCGCATTTGAACAGAACGCGCTGGAAGGTATGCTGGATACGCTGAAG
AAAGATATCGCCCTGGGGCAAGAGTTCGTTAATAAGTAA

# Drug_Target_3_General_Function:
Energy production and conversion

# Drug_Target_3_General_References:
11214793	Pupo GM, Lan R, Reeves PR, Baverstock PR: Population genetics of Escherichia coli in a natural population of native Australian rats. Environ Microbiol. 2000 Dec;2(6):594-610.
1507230	Hall MD, Levitt DG, Banaszak LJ: Crystal structure of Escherichia coli malate dehydrogenase. A complex of the apoenzyme and citrate at 1.87 A resolution. J Mol Biol. 1992 Aug 5;226(3):867-82.
2993232	Sutherland P, McAlister-Henn L: Isolation and expression of the Escherichia coli gene encoding malate dehydrogenase. J Bacteriol. 1985 Sep;163(3):1074-9.
3299262	McAlister-Henn L, Blaber M, Bradshaw RA, Nisco SJ: Complete nucleotide sequence of the Escherichia coli gene encoding malate dehydrogenase. Nucleic Acids Res. 1987 Jun 25;15(12):4993.
3322223	Vogel RF, Entian KD, Mecke D: Cloning and sequence of the mdh structural gene of Escherichia coli coding for malate dehydrogenase. Arch Microbiol. 1987;149(1):36-42.
7028159	Fernley RT, Lentz SR, Bradshaw RA: Malate dehydrogenase: isolation from E. coli and comparison with the eukaryotic mitochondrial and cytoplasmic forms. Biosci Rep. 1981 Jun;1(6):497-507.
8108402	Boyd EF, Nelson K, Wang FS, Whittam TS, Selander RK: Molecular genetic basis of allelic polymorphism in malate dehydrogenase (mdh) in natural populations of Escherichia coli and Salmonella enterica. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1280-4.
8506346	Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C: Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5011-5.
8670822	Nystrom T, Larsson C, Gustafsson L: Bacterial defense against aging: role of the Escherichia coli ArcA regulator in gene expression, readjusted energy flux and survival during stasis. EMBO J. 1996 Jul 1;15(13):3219-28.
9190829	Charnock C: Structural studies of malate dehydrogenases (MDHs): MDHs in Brevundimonas species are the first reported MDHs in Proteobacteria which resemble lactate dehydrogenases in primary structure. J Bacteriol. 1997 Jun;179(12):4066-70.
9199437	Pupo GM, Karaolis DK, Lan R, Reeves PR: Evolutionary relationships among pathogenic and nonpathogenic Escherichia coli strains inferred from multilocus enzyme electrophoresis and mdh sequence studies. Infect Immun. 1997 Jul;65(7):2685-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.
9600841	Wilkins MR, Gasteiger E, Tonella L, Ou K, Tyler M, Sanchez JC, Gooley AA, Walsh BJ, Bairoch A, Appel RD, Williams KL, Hochstrasser DF: Protein identification with N and C-terminal sequence tags in proteome projects. J Mol Biol. 1998 May 8;278(3):599-608.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
63

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
32338

# Drug_Target_3_Name:
Malate dehydrogenase

# Drug_Target_3_Number_of_Residues:
312

# Drug_Target_3_PDB_ID:
2CMD

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_3_Protein_Sequence:
>Malate dehydrogenase
MKVAVLGAAGGIGQALALLLKTQLPSGSELSLYDIAPVTPGVAVDLSHIPTAVKIKGFSG
EDATPALEGADVVLISAGVARKPGMDRSDLFNVNAGIVKNLVQQVAKTCPKACIGIITNP
VNTTVAIAAEVLKKAGVYDKNKLFGVTTLDIIRSNTFVAELKGKQPGEVEVPVIGGHSGV
TILPLLSQVPGVSFTEQEVADLTKRIQNAGTEVVEAKAGGGSATLSMGQAAARFGLSLVR
ALQGEQGVVECAYVEGDGQYARFFSQPLLLGKNGVEERKSIGTLSAFEQNALEGMLDTLK
KDIALGEEFVNK

# Drug_Target_3_Reaction:
(S)-malate + NAD+ = oxaloacetate + NADH + H+

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes the reversible oxidation of malate to oxaloacetate

# Drug_Target_3_SwissProt_ID:
P61889

# Drug_Target_3_SwissProt_Name:
MDH_ECOLI

# Drug_Target_3_Synonyms:
EC 1.1.1.37

# Drug_Target_3_Theoretical_pI:
5.46

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
U82598

# Drug_Target_4_GenBank_ID_Protein:
1778535

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
citC

# Drug_Target_4_Gene_Sequence:
>1146 bp
TCATGCGGGGGTCTTTTGACGAGCTGCCGCGTCCTGGCGGGAGTGCTCAAGCAGGTTCTG
CAAATAATGCAGCGTGACTGCAGGGACCAGCGGCGCGATAGCCGTGAGATCGTTTTTCGC
CAGCAGTTGACGTACCCGGGAAGCGGATATCGGCATCTCCTGGTAACGCAGCCGCTCAAT
TTCAACCAGTTCGATGGGCGGTGCGGAGATAGTCGGCGTTTCCAGCCAGTAGCGCATATC
CTGGTTGTACTGGGCGGTAACGCGACAAAAGGGTTCAGTACCGACAAAGCGGTGAGTTAC
ACCCAGCGCGGGAGCGAGGTACTGACGGAAAATCTTCAGATCAATTTCGGTGTAACAATG
GTTAATGACGCTCTGTTCTTTAATGAAGTAGCAAGGGAACGTAGCGCGGGAGATGATGTA
TTCGGAGCCACGATGCACAGTCAGGCGTGGAATATCGGCGGTGCCTTTTAACACCAAATC
CAGCCGGTCTTCATAGGGGAAGCGTGAAGAATCTTCTTTGACTAAAAACAGATGCAACCA
GTCGCACTGTGCCGCAGCCTGTTGAATCAGATAACGGTGACCATTCGTAAAGGGATTGGC
GTTCATCACAATGCAGCCAATCTTGTTCCCTGGATGACGAAATTTTTTCAGCGATTCGGC
ATAGCGTTTCAGTCGCGTGGCGCTGTTTTCCATCAGCACCATCACGCCGGGTACGCTGGT
CAGCGTGGAAAAACCGCACTGGCGGAACAGCGCCTCGTATTCGGTTTTGGTATAAATAAA
CAGATGCGTGCTGTGCCGCTCATAGGCGAGGTTTATCAATTCAGTGGCTAATGTCAGCGC
CAGTCCTTCACCGCGGACGGATTCACTGATAGCAACGCATTTAATAATATTTCCGGCAAT
TCCACCGCACGCGATAAGCTTTTCATCGCGGGTTACGGTAATAAATACTTCGACTGTGGT
GTCAACGCTCAAATCATTTTCATGCAGGAATTGGGCGATTTCCGCCATTTTTTTATTTTC
TGAACGTTTTACGCGGGTGAAAATATCATTGCCGAACATAATAAATAGTATCCTGAAGGT
GCATGTTGTTATCGATTTGCAACGAATGTTGTTCAATGTTGCAAACTGATAACCTTTTAT
TTTCAC

# Drug_Target_4_General_Function:
Energy production and conversion

# Drug_Target_4_General_References:
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
893

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
40078

# Drug_Target_4_Name:
[Citrate [pro-3S]-lyase] ligase

# Drug_Target_4_Number_of_Residues:
352

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00583	Acetyltransf_1
PF08218	Citrate_ly_lig

# Drug_Target_4_Protein_Sequence:
>[Citrate [pro-3S]-lyase] ligase
MFGNDIFTRVKRSENKKMAEIAQFLHENDLSVDTTVEVFITVTRDEKLIACGGIAGNIIK
CVAISESVRGEGLALTLATELINLAYERHSTHLFIYTKTEYEALFRQCGFSTLTSVPGVM
VLMENSATRLKRYAESLKKFRHPGNKIGCIVMNANPFTNGHRYLIQQAAAQCDWLHLFLV
KEDSSRFPYEDRLDLVLKGTADIPRLTVHRGSEYIISRATFPCYFIKEQSVINHCYTEID
LKIFRQYLAPALGVTHRFVGTEPFCRVTAQYNQDMRYWLETPTISAPPIELVEIERLRYQ
EMPISASRVRQLLAKNDLTAIAPLVPAVTLHYLQNLLEHSRQDAAARQKTPA

# Drug_Target_4_Reaction:
ATP + acetate + [citrate (pro-3S)-lyase](thiol form) = AMP + diphosphate + [citrate (pro-3S)-lyase](acetyl form)

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Acetylation of prosthetic group (2-(5''-phosphoribosyl)- 3'-dephosphocoenzyme-A) of the gamma subunit of citrate lyase

# Drug_Target_4_SwissProt_ID:
P77390

# Drug_Target_4_SwissProt_Name:
CITC_ECOLI

# Drug_Target_4_Synonyms:
Acetate:SH-citrate lyase ligase
Citrate lyase synthetase
EC 6.2.1.22

# Drug_Target_4_Theoretical_pI:
8.21

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB00336
